Acorda Therapeutics Inc. (ACOR) and AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) Comparing side by side

Both Acorda Therapeutics Inc. (NASDAQ:ACOR) and AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) are each other’s competitor in the Biotechnology industry. Thus the contrast of their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acorda Therapeutics Inc. 409.40M 0.89 5.72M -0.43 0.00
AgeX Therapeutics Inc. 1.54M 71.61 10.40M -0.21 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Acorda Therapeutics Inc. and AgeX Therapeutics Inc.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Acorda Therapeutics Inc. -1.40% -1% -0.4%
AgeX Therapeutics Inc. -675.32% -82% -63.9%

Liquidity

Acorda Therapeutics Inc.’s Current Ratio and Quick Ratio are 4.3 and 4 respectively. The Current Ratio and Quick Ratio of its competitor AgeX Therapeutics Inc. are 3.2 and 3.2 respectively. Acorda Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to AgeX Therapeutics Inc.

Analyst Ratings

Acorda Therapeutics Inc. and AgeX Therapeutics Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acorda Therapeutics Inc. 0 1 1 2.50
AgeX Therapeutics Inc. 0 0 0 0.00

The upside potential is 338.25% for Acorda Therapeutics Inc. with average target price of $33.

Institutional and Insider Ownership

The shares of both Acorda Therapeutics Inc. and AgeX Therapeutics Inc. are owned by institutional investors at 0% and 23.8% respectively. 1.5% are Acorda Therapeutics Inc.’s share held by insiders. Competitively, 43.8% are AgeX Therapeutics Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acorda Therapeutics Inc. -4% -5.37% -26.85% -43.46% -54.52% -27.6%
AgeX Therapeutics Inc. 0.44% 2.24% 11.22% 0% 0% 52.51%

For the past year Acorda Therapeutics Inc. has -27.6% weaker performance while AgeX Therapeutics Inc. has 52.51% stronger performance.

Summary

Acorda Therapeutics Inc. beats on 8 of the 11 factors AgeX Therapeutics Inc.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in ParkinsonÂ’s disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in ParkinsonÂ’s disease; SYN120, which is in Phase II clinical trial to treat ParkinsonÂ’s disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and WomenÂ’s Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.